Does lisinopril cause gynaecomastia? This is a reasonable concern for men taking this widely prescribed ACE inhibitor for hypertension, heart failure, or diabetic nephropathy. Gynaecomastia — benign enlargement of male breast tissue — can occasionally be triggered by medicines, and understanding whether lisinopril is implicated is important for both patients and clinicians. This article examines the current evidence, explores better-established drug causes of gynaecomastia, and outlines when to seek medical advice, in line with NICE, NHS, and MHRA guidance.

Can Lisinopril Cause Gynaecomastia?

Gynaecomastia is not a recognised adverse effect of lisinopril according to its MHRA-approved SmPC, and no established causal link is cited in NICE or NHS guidance.

Experiencing these side effects? Our pharmacists can help you navigate them →

Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor prescribed in the UK for conditions including hypertension, heart failure, and diabetic nephropathy. It works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby reducing blood pressure and decreasing the workload on the heart.

Gynaecomastia — the benign enlargement of glandular breast tissue in males — is not a recognised or common adverse effect of lisinopril according to its Summary of Product Characteristics (SmPC) as held on the MHRA's medicines database (medicines.org.uk). Unlike some other cardiovascular medicines, ACE inhibitors are not known to directly interfere with sex hormone pathways in a way that would predictably cause breast tissue changes.

It is important to note that no established causal link between lisinopril and gynaecomastia is cited in standard NICE or NHS guidance. However, medicine-induced gynaecomastia can sometimes be difficult to attribute with certainty, particularly in patients taking multiple medicines or with underlying health conditions that independently affect hormone balance. If you are concerned about any breast changes whilst taking lisinopril, speak to your GP or pharmacist before making any changes to your treatment.

How Common Is Gynaecomastia as a Medicine Side Effect?

Drug-induced gynaecomastia accounts for approximately 10–25% of all cases and results from an oestrogen–androgen imbalance in breast tissue triggered by various medicines.

Gynaecomastia affects a significant proportion of males at various life stages. When medicines are the cause, this is referred to as drug-induced gynaecomastia, which is estimated to account for approximately 10–25% of all gynaecomastia cases in clinical practice, according to NICE Clinical Knowledge Summaries (CKS) on gynaecomastia.

The condition arises when there is an imbalance between oestrogen and androgen activity in breast tissue — either through increased oestrogen effect, reduced androgen effect, or both. Medicines can trigger this through several mechanisms:

• Increasing oestrogen levels or activity (e.g., oestrogen-containing preparations)

• Blocking androgen receptors (e.g., spironolactone, bicalutamide)

• Reducing testosterone production (e.g., GnRH analogues)

• Increasing prolactin levels (e.g., antipsychotics, metoclopramide)

• Unknown or mixed mechanisms (e.g., some antihypertensives, proton pump inhibitors)

The onset of drug-induced gynaecomastia can range from weeks to years after starting a medicine, which can make identification challenging. NICE CKS guidance on gynaecomastia recommends a thorough medication review as part of the initial assessment, underscoring how important it is to consider all prescribed, over-the-counter, and herbal medicines when investigating new breast tissue changes in males.

Evidence and Reported Cases Linked to Lisinopril

Evidence linking lisinopril to gynaecomastia is limited to isolated case reports; no clear pharmacological mechanism exists and the MHRA pharmacovigilance signal remains weak.

The evidence directly linking lisinopril to gynaecomastia is limited and largely confined to isolated case reports rather than robust clinical trial data or established pharmacovigilance signals. A small number of case reports in medical literature have described the development of gynaecomastia in male patients taking ACE inhibitors, including lisinopril, with resolution or improvement following discontinuation of the medicine — a pattern known as dechallenge, which is considered supportive (though not conclusive) evidence of a possible relationship.

The MHRA's Yellow Card scheme, which collects spontaneous adverse drug reaction reports in the UK, has received spontaneous reports associating ACE inhibitors with gynaecomastia; however, spontaneous reporting systems are subject to significant underreporting and cannot establish causality on their own. The overall signal for lisinopril specifically remains weak compared to medicines with well-established links to gynaecomastia. If you suspect lisinopril or any other medicine has caused a side effect, you can report this directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

From a pharmacological standpoint, there is no clearly defined mechanism by which lisinopril would be expected to cause gynaecomastia. ACE inhibitors do not significantly alter sex hormone-binding globulin, testosterone, or oestradiol levels in most patients. Some researchers have speculated that bradykinin accumulation — a known consequence of ACE inhibition — could theoretically influence local tissue responses, but this remains speculative and unproven. In summary, while a causal link cannot be entirely excluded on the basis of rare case reports, the current evidence does not support lisinopril as a recognised cause of gynaecomastia.

Other Medicines and Causes of Gynaecomastia to Consider

Spironolactone, digoxin, bicalutamide, and GnRH analogues have well-established links to gynaecomastia and should be considered before attributing the condition to lisinopril.

Given the limited evidence linking lisinopril to gynaecomastia, it is clinically important to consider other, better-established causes when a patient presents with this condition. Many men with hypertension or heart failure — the same conditions for which lisinopril is prescribed — are also taking other medicines with stronger associations with gynaecomastia.

Medicines with well-established links to gynaecomastia include:

• Spironolactone — an aldosterone antagonist frequently used in heart failure; one of the most common drug causes due to its anti-androgenic properties

• Digoxin — has oestrogenic activity and is used in atrial fibrillation and heart failure

• Bicalutamide and other anti-androgens — used in prostate cancer; strongly implicated

• GnRH analogues (e.g., goserelin) — used in prostate cancer; reduce testosterone production

• Finasteride — used for benign prostatic hyperplasia and male-pattern hair loss

• Anabolic steroids and testosterone supplements — commonly implicated

• Some antipsychotics (e.g., haloperidol, risperidone) — via hyperprolactinaemia

Medicines with reported but less certain associations (based largely on case reports or series):

• Calcium channel blockers (e.g., amlodipine) — reported in some case series; evidence is limited

• Proton pump inhibitors (e.g., omeprazole) — reported with long-term use; evidence remains limited and not universally accepted

Recreational substances — anabolic steroids and alcohol have recognised associations. The link with cannabis is uncertain and remains controversial in the literature; heroin is sometimes cited but associations are often confounded by comorbidities and nutritional status.

Beyond medicines, gynaecomastia can result from physiological causes (puberty, ageing), hypogonadism, liver cirrhosis, hyperthyroidism, chronic kidney disease, or rarely testicular or adrenal tumours. A thorough clinical assessment, including blood tests (LH, FSH, testosterone, oestradiol, prolactin, liver and renal function, and thyroid function), is recommended to exclude underlying pathology before attributing the condition to any medicine. Where a testicular or other malignancy is suspected, serum hCG (and in some cases AFP) should also be measured, and testicular examination with ultrasound considered, in line with NICE CKS guidance on gynaecomastia.

When to Speak to Your GP or Pharmacist

Any breast swelling, hard lump, nipple discharge, or rapidly progressive enlargement in a male should prompt a GP assessment to exclude male breast cancer and other serious causes.

If you are taking lisinopril and notice breast swelling, tenderness, or a firm lump beneath the nipple, it is advisable to speak to your GP or pharmacist promptly. Whilst gynaecomastia is usually benign, breast changes in males should always be assessed to rule out more serious conditions, including male breast cancer, which, although rare, accounts for approximately 1% of all breast cancer diagnoses in the UK (Cancer Research UK).

You should contact your GP if you experience:

• Unilateral (one-sided) breast swelling or a hard, irregular lump

• Nipple discharge, skin changes, or nipple inversion

• Rapidly progressive breast enlargement

• Associated symptoms such as testicular pain or swelling

• Breast changes alongside unexplained weight loss or fatigue

In line with NICE guideline NG12 (Suspected Cancer: Recognition and Referral), GPs should consider an urgent two-week wait referral to a breast clinic for any male with a unilateral, firm, subareolar mass with or without nipple discharge, or any other breast presentation that raises clinical concern — irrespective of age. Any clinically suspicious mass warrants urgent referral.

Your GP will take a full history, including a detailed medication review, and may arrange blood tests or refer you to a breast clinic as appropriate. Do not stop taking lisinopril or any prescribed medicine without first speaking to a healthcare professional, as abrupt discontinuation of antihypertensive therapy can carry significant cardiovascular risks.

Your pharmacist can also be a valuable first point of contact — they can review your full medication list, identify potential drug interactions or side effects, and advise whether a GP appointment is warranted.

Managing Side Effects and Reviewing Your Treatment

If lisinopril is suspected to contribute to gynaecomastia, a clinician may switch to an ARB such as losartan; do not stop lisinopril without medical advice due to cardiovascular risks.

If a medicine is suspected to be contributing to gynaecomastia, the standard clinical approach is to review whether the medicine is still necessary, whether the dose can be reduced, or whether an alternative agent with a lower risk profile can be substituted. This decision must always be made in partnership with your prescribing clinician, balancing the potential side effect against the clinical benefit of the treatment.

For patients taking lisinopril specifically, the medicine plays an important role in cardiovascular and renal protection. If gynaecomastia is suspected to be drug-related but lisinopril is considered the most likely contributing factor after excluding other causes, your GP may consider switching to an angiotensin receptor blocker (ARB) such as losartan or candesartan. ARBs work through a related but distinct mechanism and are not associated with gynaecomastia. Switching from an ACE inhibitor to an ARB in cases of ACE inhibitor intolerance is supported by NICE guideline NG136 (Hypertension in Adults: Diagnosis and Management).

In cases where gynaecomastia is confirmed and persists despite medication review, further management options may include:

• Watchful waiting — mild cases may resolve spontaneously, particularly if the causative medicine is stopped early

• Medical therapy — tamoxifen or raloxifene may be considered in persistent or painful cases; these are used off-label for this indication and should be initiated under specialist guidance only, following a careful discussion of risks and benefits (NICE CKS: Gynaecomastia)

• Surgical referral — for longstanding, fibrotic, or cosmetically significant gynaecomastia that has not responded to other measures

If you believe lisinopril or another medicine has caused a side effect, you or your clinician can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Reporting helps build the evidence base for medicine safety in the UK.

Ultimately, any new or unexplained breast change in a male patient warrants proper clinical evaluation. Medicines such as lisinopril should not be discontinued without medical advice, and a collaborative approach between patient and clinician will ensure both safety and effective symptom management.

Frequently Asked Questions